

## ENSAYOS CLÍNICOS MELANOMA, TUMORES CUTÁNEOS, SNC, PULMÓN, SARCOMA Y CABEZA CUELLO.

### - MELANOMA

#### **CA224-098 (RELATIVITY-098)**

*"A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab and Nivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma"*

<https://clinicaltrials.gov/ct2/show/NCT05002569>

#### **BNT111-01**

*"Open-Label, randomized Phase II trial with BNT111 and cemiplimab in combination or as single agents in patients with anti-PD1-refractory/relapsed, unresectable Stage III or IV melanoma"*

<https://clinicaltrials.gov/ct2/results?cond=&term=BNT111-01&cntry=&state=&city=&dist=>

#### **REGENERON (R2810-ONC-1788)**

*"A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPILIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA"*

<https://clinicaltrials.gov/ct2/results?cond=&term=R2810-ONC-1788&cntry=&state=&city=&dist=>

#### **C4221016 (STARBOARD) CERRADA FASE SLI, PENDIENTE APERTURA FASE 3**

*"A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma"*

<https://www.clinicaltrials.gov/ct2/show/NCT04657991?term=C4221016&cond=MELANOMA&draw=2&rank=1>

#### **ALKS 4230.006 (ARTISTRY-6)**

*"Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6A"*

<https://www.clinicaltrials.gov/ct2/results?cond=&term=ALKS+4230-006&cntry=&state=&city=&dist=>

- CABEZA Y CUELLO

**AN2025H0301 (BURAN)**

*"The BURAN Study of Buparlisib (AN2025) In Combination with Paclitaxel Compared to Paclitaxel Alone, in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma"*

<https://www.clinicaltrials.gov/ct2/show/NCT04338399?term=AN2025H0301&cond=Head+and+Neck+Cancer&draw=2&rank=1>

- TIROIDES

**J2G-MC-JZJB(LIBRETTO-531)**

*"A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer"*

<https://clinicaltrials.gov/ct2/results?cond=&term=J2G-MC-JZJB&cntry=&state=&city=&dist=>

- PULMÓN

**BO29554 (B-FAST)**

*"A PHASE II/III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TARGETED THERAPIES AS TREATMENTS FOR PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING ACTIONABLE SOMATIC MUTATIONS DETECTED IN BLOOD (BFAST: BLOOD FIRST ASSAY SCREENING TRIAL)"*

<https://clinicaltrials.gov/ct2/show/NCT03178552?term=BO29554&rank=1>

**TAK 788-3001 (EXCLAIM-2)**

*"A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutation"*

<https://clinicaltrials.gov/ct2/results?cond=&term=TAK+788+3001&cntry=&state=&city=&dist=>

**GO41854 (SKYSCRAPER 03)**

*A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB AND TIRAGOLUMAB COMPARED WITH DURVALUMAB IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER WHO HAVE NOT PROGRESSED AFTER CONCURRENT PLATINUM-BASED CHEMORADIATION*

<https://clinicaltrials.gov/ct2/results?cond=&term=GO41854&cntry=&state=&city=&dist=&Search=Search>

**BO42598 (SKYSCRAPER 06)**

*A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer (SKYSCRAPER-06)*

<https://clinicaltrials.gov/ct2/results?cond=&term=BO42592&cntry=&state=&city=&dist=>

### **BO42864 (AcceleRET-Lung)**

*A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer*

<https://clinicaltrials.gov/ct2/results?cond=&term=BLU+6672303&cntry=&state=&city=&dist=&Search=Search>

### **CINC280A2301**

*A phase III, randomized, controlled, open-label, multicenter, global study of capmatinib versus SoC docetaxel chemotherapy in previously treated patients with EGFR wt, ALK negative, locally advanced or metastatic (stage IIIB/IIIC or IV) NSCLC harboring MET exon 14 skipping mutation*

<https://clinicaltrials.gov/ct2/results?cond=&term=CINC280A2301&cntry=&state=&city=&dist=&Search=Search>

### **PAPILLON (61186372NSC3001)**

*A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions*

<https://clinicaltrials.gov/ct2/results?recrs=&cond=&term=61186372NSC3001&cntry=&state=&city=&dist=>

### **ZEAL (213400)**

*Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo and Pembrolizumab as Maintenance Therapy*

<https://clinicaltrials.gov/ct2/results?cond=&term=213400&cntry=&state=&city=&dist=&Search=Search>

### **APL-101-01 (SPARTA)**

*APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors*

<https://www.clinicaltrials.gov/ct2/show/NCT03175224?term=APL-101-01&draw=2&rank=1>

### **Amgen 20170543 (CodeBreak 100)**

*A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100)*

<https://clinicaltrials.gov/ct2/show/NCT04933695?cond=AMG510&draw=2&rank=2>

### **EORTC-1825-LCG (ALKALINE)**

*Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients*

<https://www.clinicaltrials.gov/ct2/show/NCT04127110?term=ALKALINE&cond=Lung+Cancer&draw=2&rank=1>

### **D6185C00001 (HUDSON)**

*This is an open-label, multi-centre, umbrella Phase II study in patients with metastatic NSCLC who have progressed on an anti-PD-1/PD-L1 containing therapy. This study is modular in design, allowing initial assessment of the efficacy, safety, and tolerability of multiple treatment arms.*

<https://clinicaltrials.gov/ct2/show/NCT03334617?term=HUDSON&draw=2&rank=1>

### **MARIPOSA-2 (61186372NSC3002)**

*A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure*

<https://clinicaltrials.gov/ct2/show/NCT04988295?term=61186372NSC3002&draw=2&rank=1>

### **MO43576 (Imscin-002)**

*A RANDOMIZED, MULTICENTER, OPEN-LABEL CROSS-OVER STUDY TO EVALUATE PARTICIPANT AND HEALTHCARE PROFESSIONAL REPORTED PREFERENCE FOR SUBCUTANEOUS ATEZOLIZUMAB COMPARED WITH INTRAVENOUS ATEZOLIZUMAB FORMULATION IN PARTICIPANTS WITH NON SMALL CELL LUNG CANCER.*

<https://clinicaltrials.gov/ct2/show/NCT05171777>

### **GS-US-577-6153 (Evoke-01)**

*Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy*

<https://clinicaltrials.gov/ct2/show/NCT05089734?term=GS-US-577-6153&draw=2&rank=1>

### **GS-US-576-6220 (Evoke-02)**

*Study of Sacituzumab Govitecan-hzy Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations*

<https://clinicaltrials.gov/ct2/results?cond=&term=GS-US-576-6220+&cntry=&state=&city=&dist=>

## **- SARCOMAS**

### **GEIS 42**

*“Three versus five years of adjuvant imatinib as treatment of patients with operable GIST with a high risk for recurrence: A randomised phase III study”*

<https://clinicaltrials.gov/ct2/show/NCT02413736?term=SSGXXII&rank=1>

### **GEIS-75 (Synergias)**

*"Multicohort Trial of Trabectedin and Low-dose Radiation Therapy in Advanced/Metastatic Sarcomas"*

<https://www.clinicaltrials.gov/ct2/show/NCT05131386?term=geis-75&draw=2&rank=1>

### **GEIS-35 (rEECur)**

*"International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma"*

[No link available](#)

### **FaR-RMS**

*"Treatment of Recurrent and Primary Refractory Ewing Sarcoma" FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma*

<https://clinicaltrials.gov/ct2/show/NCT04625907?term=faR-RMS&draw=2&rank=1>

### **GEIS-51**

*"Phase II Multicenter Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression"*

<https://www.clinicaltrials.gov/ct2/results?cond=&term=GEIS-51&cntry=&state=&city=&dist=>

### **PH-L19TNFDOX2-03/16 FIBROSARC**

*"A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma"*

<https://www.clinicaltrials.gov/ct2/results?cond=&term=PH-L19TNFDOX2-03%2F16&cntry=&state=&city=&dist=>

### **J1S-MC-JP04**

*A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Irinotecan and Temozolomide in Participants With Relapsed or Refractory Ewing's Sarcoma*

<https://clinicaltrials.gov/ct2/show/NCT05440786?term=J1S-MC-JP04&draw=2&rank=1>